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Abstract
Senescence marker protein (SMP30), also known as regucalcin, is a 34 kDa cytosolic marker protein of aging which plays an
important role in intracellular Ca
2+ homeostasis, ascorbic acid biosynthesis, oxidative stress, and detoxification of chemical
warfare nerve agents. In our goal to investigate the activity of SMP30 for the detoxification of nerve agents, we have
produced a recombinant adenovirus expressing human SMP30 as a fusion protein with a hemaglutinin tag (Ad-SMP30-HA).
Ad-SMP30-HA transduced the expression of SMP30-HA and two additional forms of SMP30 with molecular sizes ,28 kDa
and 24 kDa in HEK-293A and C3A liver cells in a dose and time-dependent manner. Intravenous administration of Ad-
SMP30-HA in mice results in the expression of all the three forms of SMP30 in the liver and diaphragm. LC-MS/MS results
confirmed that the lower molecular weight 28 kDa and 24 kDa proteins are related to the 34 kDa SMP30. The 28 kDa and
24 kDa SMP30 forms were also detected in normal rat liver and mice injected with Ad-SMP30-HA suggesting that SMP30
does exist in multiple forms under physiological conditions. Time course experiments in both cell lines suggest that the
28 kDa and 24 kDa SMP30 forms are likely generated from the 34 kDa SMP30. Interestingly, the 28 kDa and 24 kDa SMP30
forms appeared initially in the cytosol and shifted to the particulate fraction. Studies using small molecule inhibitors of
proteolytic pathways revealed the potential involvement of b and c-secretases but not calpains, lysosomal proteases,
proteasome and caspases. This is the first report describing the existence of multiple forms of SMP30, their preferential
distribution to membranes and their generation through proteolysis possibly mediated by secretase enzymes.
Citation: Arun P, Aleti V, Parikh K, Manne V, Chilukuri N (2011) Senescence Marker Protein 30 (SMP30) Expression in Eukaryotic Cells: Existence of Multiple Species
and Membrane Localization. PLoS ONE 6(2): e16545. doi:10.1371/journal.pone.0016545
Editor: Vladimir Uversky, University of South Florida College of Medicine, United States of America
Received September 8, 2010; Accepted December 21, 2010; Published February 9, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: The work is supported by funds from Defense Threat Reduction Agency (DTRA, Project # D0024_07_WR_C). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nageswararao.chilukuri@us.army.mil
Introduction
Senescence marker protein 30 (SMP30) was identified from rat
liver in 1992 as an aging factor, the expression of which decreases
withage in an androgen independent manner suggesting its possible
roles in age related physiologic and pathologic conditions [1–3].
Regucalcin was known since 1978 as a calcium-binding protein
without the typical Ca
2+ binding EF-motif and has been extensively
studied foritsrole inthe maintenanceofCa
2+ homeostasisand Ca
2+
signaling in rat liver and kidney cells [4–7]. Following the cloning
and characterization of genes encoding these proteins, it became
clear that SMP30 and regucalcin are one and the same with 299
amino acids and an estimated molecular weight of 33387 Daltons
[2–8]. Nonetheless, there appears to be no consensus on the
nomenclature forthisprotein andweuseSMP30inour manuscript.
SMP30 has a highly conserved structure across various animal
species [9,10] and is widely distributed in different tissues including
liver, kidney, brain, testis, lungs, adrenal gland, stomach, ovary,
uterus and epidermis [11]. Immunohistochemical and western blot
analysis shows that SMP30 is localized in the cytosol and nucleus of
hepatocytes [12] and in the case of kidney, the immunoreactivity
was primarily in renal proximal tubular epithelia [2].
The reported functions and activities of SMP30/regucalcin are
varied. One of the major roles described for SMP30 is in
maintaining Ca
2+ homeostasis by activating enzymes involved in
the regulation of Ca
2+ pump localized in the plasma membrane,
microsomesandmitochondriaofdifferentcelltypes[5].SMP30can
bind to Ca
2+ even though it lacks the known Ca
2+ binding motif
such as EF-hand [13]. In the nucleus, SMP30 is believed to be
involved in the regulation of protein kinases, protein phosphatases
and deoxyribonucleic acid and ribonucleic acid biosynthesis [5].
Over expression of SMP30 in rats leads to osteoporosis [14] and
hyperlipidemia [15] while SMP30 deficiency in mice causes
accumulation of neutral lipids and phospholipids in the liver [16]
showing its critical roles in bone and lipid metabolism. Studies
conducted using SMP30 knock-out mice indicate that brain SMP30
has a protective role against oxidative damage without influencing
the enzymes involved in antioxidant protection [17]. SMP30 also
possesses gluconolactonase activity and hence play an important
role in ascorbic acid biosynthesis in the liver [18].
Our interest in SMP30 grew out of three studies which reported
that SMP30 and/or a structurallyrelated protein frommouseand rat
livers hydrolyzed disiopropylfluorophosphate (DFP) and chemical
warfare nerve agents including soman, sarin, VX,and tabun [19–21].
In addition, SMP30 knock-out mice lacked DFPase activity implying
that SMP30 may be the DFP hydrolyzing enzyme in the liver and
hence it can be a potent catalytic bioscavenger against nerve agents
[19]. Even though there are structural similarities between SMP30
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bioscavenger, the inability of SMP30 to hydrolyze PON1 specific
substrates makes SMP30 distinct from PON family [19].
Mitigating the risk posed by the potential use of nerve agents in
warfare as well as in civilian populations is strategic and high
priority. In order to determine whether human SMP30 functions
in the hydrolysis of nerve agents in vivo, we have produced a
recombinant adenovirus expressing human SMP30 as a fusion
protein with a hemaglutinin tag (Ad-SMP30-HA). In this
manuscript, we present novel observations from Ad-SMP30-HA
transduced expression of SMP30-HA in human embryonic kidney
epithelial cells (HEK-293A) and hepatoma carcinoma (C3A) cells.
In addition to the 34 kDa intact SMP30, two additional forms of
SMP30 with molecular sizes of ,28 kDa and ,24 kDa were
consistently and reproducibly detected in cell extracts raising the
possibility that the virus-expressed SMP30 underwent intracellular
processing. While a significant portion of 34 kDa SMP30 in cells
was cytosolic, a substantial majority of the protein was also
localized to crude mitochondrial fraction and microsomal
membranes. On the other hand, the 28 kDa and 24 kDa lower
molecular weight forms appeared initially in the cytosol and
shifted to the particulate fraction. All the three forms of SMP30-
HA were expressed in the liver and diaphragm of mice injected
with Ad-SMP30-HA. The 28 kDa and 24 kDa SMP30 forms were
also detected in normal rat liver suggesting that native enzyme also
undergoes a similar processing. Inhibitors of calpains, lysosomal
proteases, the proteasome and caspases had no effect on SMP30
processing. However, inhibitors specific to both b and c-secretases
inhibited the expression of smaller SMP30 forms suggesting their
possible involvement in the processing of SMP30.
Results
Expression and dose response of Ad-SMP30 in HEK-293A
and C3A cells
Figure 1 shows the expression of SMP30 in HEK-293A cells (A)
and in C3A liver cells (B). In addition to the expected 34 kDa
protein, two additional low molecular weight proteins (,28 kDa
and 24 kDa) were also detected using the antibodies against both
HA-tag and native SMP30 protein. Expression of SMP30 increased
as the VP/cell for infection was raised in both the cell lines.
Maximal expression was achieved with 10–20 VP/cell in 293A cells
and required 20 times higher number in C3A liver cells since the
virus does not multiply in C3A cells because these cells lack the E1
gene products which are required for multiplication of the virus. E1
gene products are expressed in HEK-293A cells. The presence or
accumulation of SMP30 related low molecular weight proteins was
optimal with viral particles producing maximal SMP30 expression
in both the cell lines. These results suggest that our virus was
biologically active and transduced the expression of SMP30 in a
dose dependant manner. Immunoreactivity of the low molecular
weight proteins to both the antibodies suggest that they are likely
relatedto the 34 kDa SMP30 protein. All the three forms of SMP30
were observed on a consistent basis and repeatedly when we took
extreme precautions including quick and direct lysis into SDS-
PAGE sample buffer and making extracts in the presence of a
cocktail of protease inhibitors (results not shown). Actin controls
were used to ascertain equal sample loading across various lanes.
Confirmation of the identity of SMP30-HA and its
processed forms using LC-MS/MS
We explored the three differentforms of SMP30 further by nano-
flow LC-MS/MS after purifying partially by HA-affinity chroma-
tography. Using a SMP30 western blot as a guide, the three protein
bands from an SDS-PAGE gel were cut out separately as indicated
in Figure 2. Following the processing of the gel pieces through
standard proceduresfornano-flowLC-MS/MS,analysisofthe data
from protein bands corresponding to SMP30 and its lower
molecular weight forms showed that all the three proteins carried
the amino acid sequence of human SMP30. The 34 kDa protein
band yielded four peptide sequences of human SMP30: YFAGT-
MAEETAPAVLER, FNDGKVDPAGR, LQTVKLPVDK and
QSGGYVATIGTK; the 28 kDa protein band produced YFAGT-
MAEETAPAVLER and FNDGKVDPAGR; and the 24 kDa
protein band gave YFAGTMAEETAPAVLER. These LC-MS/
MS results confirm that the lower molecular weight proteins are
related to 34 kDa SMP30 protein and were likely formed from it.
Presence of low molecular weight forms of SMP30 in
normal rat liver
Since SMP30 has not been reported to exist in multiple forms
and to rule out the possibility that the lower molecular weight
forms are an artifact of very high levels of gene expression, we
explored for their existence in rat tissues. We chose young rat livers
that are known to make high levels of SMP30. Western blot
analysis of the liver extracts from 7 day old rat pup using the
antibody against SMP30 identified the 34 kDa form as the
predominant species. In addition, we also detected the three
additional lower molecular weight forms of SMP30, particularly
visible in lanes 2 and 3 loaded with large amounts of proteins
(Figure 3). Two lower size forms are comparable to 24 kDa and
28 kDa forms found in C3A liver cells infected with Ad-SMP30-
HA (Figure 3).
Presence of low molecular weight SMP30 forms in the
liver and diaphragm of mice injected with Ad-SMP30-HA
We investigated whether the Ad-SMP-30 is biologically active in
vivo in mice and whether the 28 kDa and 24 kDa forms of SMP30
are also formed in vivo following virus injection in mice. Mice were
injected with Ad-SMP30-HA or a control virus and 4 days later,
liver and diaphragm were processed for the presence of various
forms of SMP30 by western blotting using anti-HA antibody. The
28 kDa and 24 kDa SMP30 forms were detected in both tissues
suggesting that human SMP30 does undergo processing and exists
in multiple forms in vivo (Figure 4). No detectable amount of the
full length SMP30-HA or the processed forms were detected in the
liver and diaphragm of mice injected with a control virus.
Localization of SMP30 and its lower molecular weight
proteins
Mouse SMP30 has been detected previously in the cytoplasm,
nucleus and mitochondria, but there were no reports of the
existence of multiple forms of SMP30 and their distribution. To
gain a better understanding of the various forms of human SMP30
detected in our system and their sub-cellular distribution, we
fractionated Ad-SMP30-HA infected HEK-293A cell extracts into
cytosolic, microsomal and particulate fractions. The results in
Figure 5A show that while a significant portion of 34 kDa SMP30
protein in HEK-293A cells was cytosolic, a substantial majority of
the protein was also localized to crude mitochondrial (10,0006g
pellet) and microsomal membrane (100,0006g pellet) fractions.
Both of the lower molecular weight forms of SMP30 were also
detectable in all fractions, albeit to varying degrees. Nonetheless,
the results suggest that the lower molecular weight forms of
SMP30 are localized predominantly in the particulate fraction,
particularly mitochondria. The particulate association of these
multiple SMP30 forms is quite intriguing and merit further study.
SMP30 Exists as Multiple Species
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forms using NE-Per nuclear and cytoplasmic extraction kit from
Pierce Biotechnology according to manufacturer’s instructions.
The results shown in Figure 5B suggest that ,10% of the total
34 kDa SMP30 was nuclear in localization and the lower
molecular weight forms were also present, but barely detectable.
The amounts and distribution of different SMP30 forms in the
cytosolic or particulate fractions using the NE-Per extraction kit
are in excellent agreement with the results obtained above from
classical fractionation by centrifugation.
Time course expression of SMP30-HA and its small
molecular weight forms
It is not clear whether the low molecular weight SMP30
proteins are precursors or products of the larger 34 kDa SMP30
protein. However, the former possibility is unlikely since the
presence of optimal levels of the low molecular weight proteins
correlated with maximal expression of 34 kDa SMP30 species
(Figure 1). To support these observations, the biosynthesis and
distribution of SMP30 and its various forms was followed over a
period of 72 h in HEK-293A and C3A liver cells after infection
with Ad-SMP30-HA (Figure 6). Both the cell lines gave similar
results. The 34 kDa SMP30 initially appeared as early as 8 h in
the cytosolic fraction and gradually increased over the examined
time period of 72 h. Interestingly, near equal amounts of the
34 kDa form accumulate in the cytosol and particulate fraction as
peak levels of SMP30 are made after 24–48 h. The results also
indicate that the lower molecular weight forms begin to appear
initially in the cytosol over 16–24 h time period and gradually shift
to the particulate fraction, with the shift near complete by 72 h.
The kinetics and distribution observed in both the cell lines suggest
that the smaller molecular weight proteins are likely derived from
the 34 kDa protein and preferentially associate with the
particulate (mitochondria) fraction.
Effect of small molecule inhibitors on the processing of
SMP30
Proteasomal and lysosomal mechanisms are two classical
protein degradation systems and are widely used in cells. We
investigated the potential involvement of these and other
proteolytic pathways in SMP30 processing by making use of small
molecule inhibitors of proteolysis. Figure 7A–D shows the results
Figure 1. Dose response of Ad-SMP30-HA in HEK-293A cells and C3A liver cells. HEK-293A cells (A) and C3A liver cells (B) were treated with
the indicated number of viral particles for 72 h and the expression of SMP30-HA was analyzed by western blotting using SMP30 or HA antibodies.
doi:10.1371/journal.pone.0016545.g001
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presence of various inhibitors. The processing of SMP30-HA was
unaffected by chloroquine, a lysosomal inhibitor or tunicamycin, a
glycosylation inhibitor (Figure 7A). Lactacystin, an irreversible
specific inhibitor of the proteasome, also did not affect the
processing of SMP30-HA (Figure 7A). However, MG132 and PSI,
which are potent reversible non-specific inhibitors of proteasome,
significantly inhibited the processing of SMP30-HA (Figure 7A).
Since the results obtained with various inhibitors of proteasome
are conflicting, we conducted experiments to demonstrate the
involvement of proteasome in SMP30 processing directly using
Hela cell S-100 degradation mixture. The S-100 Hela proteasomal
degradation mixture contains the full complement of ubiquitin
proteasome pathway enzymes necessary for the controlled
degradation of proteins. When Hela cell S-100 mixture was used
to treat 293A cell made SMP30 proteins, the processing of 34 kDa
SMP30 protein was not affected either in the presence or absence
of MG132 (Figure 7B). These results suggest that the processing of
SMP30 protein is unlikely to be a result of the ubiquitin-
proteasome degradation pathway. We also tested the possible
involvement of calpain family of calcium-dependent, non-
lysosomal cysteine proteases in SMP30 processing by using calpain
inhibitor I and MDL28170. Both, known potent inhibitors of
calpains, did not affect the processing of SMP30-HA (Figure 7C)
which suggests that the processing of SMP30 is mediated through
proteolytic enzymes outside of the calpains. We also found that the
processing of SMP30 protein was unaffected by inhibitor of
caspases (Figure 7D), thus ruling out the possible involvement of
caspases in the proteolytic processing of 34 kDa SMP30.
The lack of effect of inhibitors of a broad range of proteases
including calpains, lysosomal proteases, the proteasome and
caspases is surprising in view of the reported existence of PEST
motifs in the amino acid sequence of SMP30 [2]. However, we did
observe that Inhibitors of both b and c-secretases blocked the
processing of SMP30, with the former showing maximum effect
(Figure 7D). While these results suggest that secretases may be
somehow involved in the processing of SMP30, extensive studies
are required to address how the apparently cytosolic SMP30 could
be processed by membrane buried secretases.
Discussion
In this study, for the first time, we present evidence that the full-
length 34 kDa SMP30 protein undergoes intracellular processing
to produce two additional forms of SMP30 with molecular sizes of
,28 kDa and 24 kDa. Two lines of evidence support that the
28 kDa and 24 kDa proteins are related to 34 kDa SMP30: 1)
polyclonal antibodies to native 34 kDa SMP30 protein reacts with
28 kDa and 24 kDa proteins suggesting the three proteins share
common antigenic epitopes, and 2) all three proteins contain one
or more peptides with identical amino acid sequences. Our results
also suggest that the processing of SMP30 happens close to the N-
terminus while the C-terminus of the protein stays intact. This is
based on the observation that the C-terminal HA-tag is recognized
by HA antibodies in both the 28 kDa and 24 kDa forms of
SMP30. Also, a peptide with amino acid sequence ‘‘YFAGT-
MAEETAPAVLER’’ that is 113 amino acids away from the N-
terminus is present in all three forms of SMP30. Our data also
Figure 3. Presence of multiple forms of SMP30 in 7 day old
normal rat pup. Rat liver cytosolic extract in increasing amounts (10,
20 and 30 mg total protein marked as 1, 2 and 3) were subjected to
western blotting using antibody against SMP30. Extracts of C3A liver
cells expressed SMP30-HA was shown for comparison.
doi:10.1371/journal.pone.0016545.g003
Figure 4. Presence of multiple forms of SMP30 in the liver and
diaphragm of mice injected with 2610
11 Ad-SMP30-HA per
animal. The animals were injected with the control virus (Ad-null, A &
B) or Ad-SMP30-HA (C & D) via the tail vein at a dose of 2610
11 VP/
animal and sacrificed on day 4 post-virus injection. Tissue homogenates
were processed by western blotting using anti-HA antibody.
doi:10.1371/journal.pone.0016545.g004
Figure 2. Schematic diagram showing the gel areas subjected
to LC-MS/MS and peptides recovered therefrom.
doi:10.1371/journal.pone.0016545.g002
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particulate (mitochondria) fraction in cells whereas the full-length
34 kDa SMP30 is equally distributed between the cytosolic and
particulate fractions. The 28 kDa and 24 kDa SMP30 forms were
also detected in normal rat liver suggesting that SMP30 does exist
in multiple forms under physiological conditions. Moreover,
Figure 5. Subcellular localization of SMP30 forms in HEK-293A cells 72 h following the infection with Ad-SMP30-HA (20 VP/cell). A,
Fractions obtained by centrifugation; B, Fractions derived using NE-PER nuclear and cytoplasmic extraction kit. The amounts of various forms from
different fractions shown in A & B represent the actual amounts shown to be present in the total whole cell lysate. Anti-HA antibody was used to
probe the western blots.
doi:10.1371/journal.pone.0016545.g005
Figure 6. Time course expression of SMP30 and its processed forms in HEK-293A cells and C3A cells. HEK-293A cell (A) and C3A cells
were treated with Ad-SMP30-HA (20 VP/cell for HEK-293A cells and 500 VP/cell for C3A liver cells) for varying periods of time, cell extracts were
prepared in M-PER buffer and separated into the particulate and cytosolic fractions. Western blotting was carried out using antibody against HA tag.
doi:10.1371/journal.pone.0016545.g006
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28 kDa and 24 kDa lower molecular weight SMP30 forms in
addition to the 34 kDa protein in the liver and diaphragm
suggesting that the existence of a processing mechanism for
34 kDa SMP30 in mice. The identity of an additional band
observed (using western blotting with anti-SMP30 antibody) in
liver extracts of normal 7 day old rat is unclear at present, but it
was absent (using western blotting with anti-HA antibody) in liver
extracts of Ad-SMP30-HA injected mice suggesting the possibility
that the anti-SMP30 antibody may have non-specific cross-
reactivity.
Stable and high level expression of SMP30/regucalcin has been
demonstrated in several eukaryotic cell lines that include human
hepatocellular carcinoma Hep G2, Rat hepatoma H4-II E, mouse
embryonic carcinoma PC19 and normal rat kidney proximal
tubular epithelial NRK 52E [10,22–26]. The levels of expression
obtained in these studies ranged from 5 to 20-fold over the vector
controls and our results with adenovirus vector achieved much
higher expression of .100-fold over the vector controls in HEK-
293A cells (Figure 1 & 6). None of the above studies reported the
formation or existence of multiple forms of SMP30. While the
reasons for the discrepancy are not completely clear at present, all
the three forms were observed in our studies on a consistent basis
and repeatedly in both the cell lines used and in vivo in mice
following Ad-SMP30-HA injection. Some of these studies may
have used the high speed centrifuged cytosolic fractions for
western blot analysis and thus missed the other species which tend
to associate preferentially with particulate fractions (see later in
Figure 7. Effect of protease inhibitors on the expression and processing of SMP30 in HEK-293A cells. A, The inhibitors, MGI32 (10 mM),
PSI (50 mM), LCys (10 mM), chloroquine (50 mM) and tunicamycin (3 mg/ml) were added along with Ad-SMP30-HA (20 VP/cell) to the cells and
incubated for 24 h; B, Effect of proteasomal degradation system on the processing of SMP30 protein expressed in HEK-293A cells in the presence or
absence of 10 mM MG132; C, Varying concentrations of calpain inhibitor I (CI, 5, 10, 15 and 20 mM) or MDL28170 (MDL, 5, 10 and 15 mM) were added
to the cells along with Ad-SMP30-HA (20 VP/cell) and incubated for 24 h; D, HEK-293A cells were treated with 20 mM caspase inhibitor I [Z-VAD(OMe)-
FMK] or 5 mM b-secretase inhibitor (Z-VLL-CHO) or 5 mM c-secretase inhibitor (Z-LLNle-CHO) or 10 mM MG132 along with Ad-SMP30-HA (20 VP/cell)
for 24 h; Equal volume of DMSO served as control. The cells were harvested, lysed with SDS-PAGE buffer containing 5% b-mercaptoethanol and SDS-
PAGE followed by western blotting was carried out using anti-HA antibody.
doi:10.1371/journal.pone.0016545.g007
SMP30 Exists as Multiple Species
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tag at the N-terminus [26] and thus could have missed the
processed forms. In any case, we used LC-MS/MS and polyclonal
antibodies to SMP30 to confirm that the lower molecular weight
proteins are related to the 34 kDa SMP30 protein.
Our sub-cellular fractionation studies show that while a
significant portion of 34 kDa SMP30 in 293A cells was cytosolic,
a substantial part of the protein was also localized to the crude
mitochondrial fraction and microsomal membranes. On the other
hand, both the lower molecular weight forms of SMP30 proteins
were found predominantly in the particulate fraction, particularly
mitochondria. The kinetics and distribution observed in both the
cell lines used suggest that the smaller molecular weight proteins
are likely formed from the 34 kDa protein in the cytosol and
preferentially migrate to mitochondria and microsomal mem-
brane. This is consistent with a report showing regucalcin (SMP30)
was localized in the mitochondria of normal rat heart and
functions to regulate Ca
2+-ATPase activity [27]. These results raise
several intriguing questions for further study. Since SMP30 is
known to be involved in the regulation of Ca
2+-homeostasis by
influencing the enzymes involved in Ca
2+ pump in the plasma
membrane, microsomal and mitochondrial membranes [5], it is
tempting to speculate for distinct yet unknown functions for the
processed forms of SMP30 in the membrane.
Several studies have reported the presence of SMP30 in the
nucleus [11,12,28] where it was demonstrated to have a role in the
regulation of nuclear function through Ca
2+ -dependent kinases,
GTPases and protein phosphatases [29–32]. Recombinant SMP30
produced in HEK-293A cells in our studies was also present in the
nucleus. Extraction of nuclear proteins using NE-Per nuclear and
cytoplasmic extraction kit from Pierce Biotechnology suggested
that ,10% of the total SMP30 is nuclear in HEK-293A cells
(Figure 5B).
Proteolysis is a cellular mechanism not only for maintaining the
concentration of proteins but also for regulating or modifying the
functions of proteins [33,34]. The major proteolytic processing
pathways involve ubiquitin-proteasome, calpains, caspases and
lysosomal proteases. Limited or controlled proteolysis through
cleavage of the protein at unique amino acid sequences is a
mechanism to modify proteins for different functions. Several
sequence motifs which signal either sensitivity to proteolysis or
entry into degradation pathways have been determined [35]. One
of those sequences called PEST sequence (sequence rich in
proline, glutamic acid or aspartic acid, serine and threonine) is
involved in targeting proteins for rapid as well as highly
conditional site specific cleavage [35,36]. One moderately strong
(amino acids 15–27) and at least four weak PEST regions (amino
acids 51–64, 112–129, 130–141 and 163–190) have been
identified in the amino acid sequence of SMP30 [2] which suggest
that SMP30 is vulnerable to proteolytic degradation. Based on
,24 kDa and ,28 kDa molecular sizes of the processed SMP30
forms, we project that the sites of proteolytic cleavage are
upstream of amino acids 80, an area in close proximity to the
PEST regions. MG132 and PSI, which are known reversible non-
specific inhibitors of proteasome, inhibited the processing of
SMP30, while the proteasome specific irreversible inhibitor, LCys,
had no effect on SMP30 processing in HEK-293A cells. These
conflicting results were reconciled by the demonstration that
SMP30 processing was unaffected by S-100 Hela degradation
mixture, which contains all reagents necessary for degradation of
proteins through the ubiquitin-proteasome pathway. As for the
inhibition observed with MG132 and PSI, it is notable that
MG132 effects in cells are not specific to the proteasome and
include several other targets including the endoplasmic reticulum
[37]. Also, MG132 can nonspecifically inhibit secretases which are
known to be involved in the proteolytic processing of various
proteins [38]. Based on these results we conclude that the
processing of SMP30 is not mediated through the ubiquitin-
proteasomal pathway.
Lysosomal proteases are also involved in the degradation of
proteins not only to inactivate proteins but also for modifying the
functions of some proteins [39]. Chloroquine, an inhibitor of
lysosomal proteases, did not affect the processing of SMP30, which
excludes the involvement of lysosomes on the processing of
SMP30. Glycosylation processes also do not appear to be involved
during the processing of SMP30 since tunicamycin did not show
any inhibition. Calpains are another family of proteolytic enzymes
containing ubiquitous and tissue-specific isoforms of Ca
2+-
activated cysteine proteases which can modify the functions of
proteins by cleaving at a limited number of specific sites [40].
Processing of SMP30 was unaffected by calpain inhibitor I and
MDL28170, which are potent inhibitors of calpains suggesting the
possibility of a calpain independent proteolytic processing of
SMP30.
Even though inhibitors to both b and c-secretases blocked the
processing of SMP30, disparate compartmentalization of SMP30
and secretases preclude us to suggest that secretases are directly
responsible for the processing of SMP30. Detailed further studies
are warranted not only for demonstrating the specific proteases
and cleavage sites involved in the processing of SMP30 but also for
understanding the physiological function(s) of the smaller forms of
SMP30. In addition, the potential involvement of alternative
splicing in generating the 28 kDa and 24 kDa SMP30 forms must
be thoroughly investigated using more sensitive methods such as
random hexamer reverse transcription semi-nested PCR or exon
specific reverse transcription semi-nested PCR [41] even though
an earlier study found no evidence of alternative splicing for
SMP30 in the coding region [42] by rapid amplification of cDNA
ends (RACE).
Materials and Methods
Chemicals and reagents
Lactacystin (LCys), MG132, tunicamycin, chloroquine, calpain
inhibitor I, MDL28170, a-actin antibody, protease inhibitor
cocktail, EZview red HA-affinity gel and HA-peptide were
obtained from Sigma-Aldrich (St. Louis, MO). EMD Biosciences
(Gibbstown, NJ) served as the source for proteasomal Inhibitor I
(PSI) caspase inhibitor I [Z-VAD (OMe)-FMK], b-secretase
inhibitor (Z-VLL-CHO) and c-secretase inhibitor (Z-LLNle-
CHO). Boston Biochem (Cambridge, MA) supplied the S-100
Hela degradation mixture. SMP30 antibody was supplied by
Cosmo Bio Co. (Denver, CO) and HA-probe antibody was from
Santa Cruz Biotechnology (Santa Cruz, CA). HEK-293A cells
were from MP Biomedicals/QBiogene Inc (Irvine, CA) and C3A
liver cells from ATCC (Manassas, VA).
Production of recombinant adenovirus expressing
human SMP30
Full-length human SMP30 cDNA was obtained from human
liver first-strand cDNA (Origene Inc., Rockville, MD) by PCR
using pfu polymerase (Stratagene, La Jolla, CA) and primers that
can amplify SMP30 coding sequences from start to stop codon.
The primer sequences were 59-ATG TCT TCC ATT AAG ATT
GAG TG-93 (forward) and 59-TCA CCC GCA TAG GAG TAG
GGA-39 (reverse). The amplified cDNA products (900 bases long)
were purified and subcloned into pCR4 Blunt-TOPO vector
(Invitrogen, Carlsbad, CA). Recombinant plasmid DNA was
SMP30 Exists as Multiple Species
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confirm its authenticity. This plasmid DNA fused with the
nucleotide sequence to code for HA-tag at its carboxyl terminus
was used for making recombinant adenovirus expressing human
SMP30 (Ad-SMP30-HA) as a fusion protein with HA-tag (Welgen
Inc., Worcester, MA). The titer of the purified virus was 1610
12
virus particles (VP)/ml of which 20 to 30% were infectious
particles among three different batches of the virus used in our
studies.
Cells and expression of recombinant SMP30-HA
HEK-293A cells and C3A liver cells were grown in 6-well cell
culture treated plates in Dulbecco’s Modified Eagle Medium
supplemented with 10% fetal bovine serum and antibiotics (penicillin
and streptomycin). One million cells per well were seeded on the 6-
well plates one day before viral infection. For dose response study in
cells, increasing number of VP/cell were added into the medium and
kept for 72 h. After 72 h, the cells were lysed with 300 mlo f
16Sodium Dodecyl Sulfate (SDS) gel loading buffer containing 5%
b-mercaptoethanol followed by incubating at 95uCf o r1 0m i n .
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and
western blotting
SDS-PAGE was carried out with precast 10% Tris-HCl gels.
After electrophoresis, the proteins were transferred to PVDF
membrane (GE Healthcare, Piscataway, NJ) using a Bio-Rad
transfer apparatus. The membrane was blocked in 4% powdered
milk for 1 h, washed once with TTBS buffer and kept overnight in
primary antibody made in 0.5% milk powder containing 0.01%
sodium azide. The primary antibodies used were either rabbit-
anti-HA polyclonal antibody (1:1000 dilution) or rabbit-anti-
SMP30 polyclonal antibody (1:1000 dilution) or mouse-a-actin
monoclonal antibody conjugated with Horse Radish Peroxidase
(1:50,000 dilution). The membrane was then washed with TTBS
five times with intermittent shaking for 8 min and incubated with
secondary antibody made in 0.5% milk powder for 1 h. The
secondary antibody used was Goat-anti-rabbit conjugated with
Horse Radish Peroxidase (KPL, Inc, Rockville, MD; 1:2500
dilution). No secondary antibody was used in the case of a-actin.
The membrane was washed again as above and the protein bands
were detected using ECL-Plus western blot detecting reagent (GE
Healthcare, Piscataway, NJ) and the chemiluminescence was
measured in a Bio-Rad image reader.
Sub-cellular localization of SMP30-HA and its processed
forms
HEK-293A cells (,50610
6) at peak SMP30 expression (72 h
post-virus infection) were washed with ice-cold phosphate buffered
saline and incubated at 4uC for 30 min in 10 mM HEPES pH 7.4
buffer containing 1 mM MgCl2, 1 mM EGTA, 0.1 mM EDTA
and protease inhibitor cocktail. Cells were then sonicated gently
and the lysate was centrifuged at 10,0006g for 10 min to obtain
the mitochondrial fraction in the pellet. The supernatant was
centrifuged further at 100,0006g for 60 min at 4uC. The
sedimented pellet (microsomes), the supernatant (cytosol) and the
mitochondrial particulate fraction were used for western blotting
using anti-HA antibody. Occasionally, particulate and crude
cytosolic fractions were prepared by lysis of cells into 200 ml M-Per
protein extraction buffer (Pierce Chemicals, Rockford, IL)
followed by centrifugation at 5000 rpm for 10 min in a
microcentrifuge. Cytosol (20 ml) was used for SDS-PAGE followed
by western blotting using anti-HA antibody. To the pellet fraction
200 ml of 1 x SDS-PAGE sample buffer containing 5% b-
mercaptoethanol was added, incubated at 95uC for 10 min and
20 ml was used for SDS-PAGE followed by western blotting using
anti-HA antibody.
Time course expression of SMP30-HA and its processed
forms in HEK-293A and C3A liver cells
Time course studies were conducted using 20 VP/cell for HEK-
293A cells and 500 VP/cell for C3A liver cells. Viral particles were
added to the wells of the 6-well plates containing one million cells per
well and incubated at 37uC for different time periods (8, 16, 24, 32, 48
and 72 h). Following incubation, cells were harvested and particulate
and cytosolic fractions were obtained using the M-Per protein
extraction buffer, and proteins were separated by SDS-PAGE followed
by western blotting as described above using anti-HA antibody.
Detection of multiple forms of SMP30 in livers of normal
rat pups
The experimental protocol was approved by the Animal Care
and Use Committee of the Uniformed Services University of the
Health Sciences (USUHS), 4301 Jones Bridge Road, Bethesda,
Maryland 20814. The title of the protocol, protocol number and
the PI: Studies on Canavan disease using rat and mouse models;
USUHS protocol number: APG-05-025; Dr. Aryan Namboodiri.
Livers from 7 day old male rat pups were homogenized using T-
Per protein isolation buffer (Pierce Chemical Co, Rockford, IL).
The 10% homogenate was centrifuged at 12,0006g for 10 min to
collect the crude cytosolic fraction. Cytosolic proteins were passed
through an Amicon micro concentrator (50 kDa molecular weight
cut off, Millipore, Billerica, MA) by centrifugation at 12,0006g for
10 min to collect the flow through fraction. The resultant solution
was concentrated using Amicon micro concentrator (10 kDa
molecular weight cut off) by centrifugation at 12,0006g for 10 min
and used for SDS-PAGE followed by western blotting using anti-
SMP30 polyclonal antibody.
Detection of multiple forms of SMP30 in the tissues of
mouse injected with Ad-SMP30-HA
These studies were carried out in accordance with the guide for the
Care and Use of Laboratory Animals as adopted by the U. S. National
Institutes of Health. The experimental protocol was approved by the
Institutional Animal Care and Use Committee of Washington
Biotechnology Inc., Simpsonville,M D .T h et i t l eo ft h ep r o t o c o l ,
protocol number and the PI: Pharmacokinetic study of SMP30 and
KIAA1363 in Swiss-Webster strain mice; WBI-PK-NC-3; Dr:
Nageswararao Chilukuri. All efforts were made to minimize animal
suffering and to reduce the number of animals used for these studies.
A d u l tf e m a l eS w i s s - W e b s t e rm i c e( 2 0t o2 5gb o d yw e i g h t ,6t o7w e e k s
old, n=10) were used for the study. Animals were given either Ad-null
(control virus) or Ad-SMP30-HA (2.0610
11 viral particles) through the
tail vein. Four days post-virus injection, the animals were sacrificed and
collected tissues including liver and diaphragm for determining SMP30
expression. Ten % tissue homogenates were made in T-Per tissue
protein isolation buffer (Pierce Chemical Co, Rockford, IL) containing
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Total
protein was measured using Bio-Rad DC protein assay kit and an
equal amount of protein sample was used for western blotting using
anti-HA antibody as described above.
In-gel digestion and LC-MS/MS to confirm the identity of
different SMP30 forms
HEK-293A cells were infected with Ad-SMP30-HA (20 VP/
cell), cultured for 48 h at 37uC, and lysed with M-Per protein
isolation buffer. The lysate was centrifuged at 10,0006g for
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affinity chromatography. Briefly, the cytosolic fraction was diluted
10-fold with equilibration buffer (20 mM Tris-HCl containing
0.1 M NaCl and 0.1 mM EDTA, pH 7.5) and passed through a
HA-affinity column. The column was washed with wash buffer
(20 mM Tris-HCl containing 1 M NaCl, pH 7.5) until the
absorbance at 280 nm of wash buffer was ,0.05. SMP30 and its
processed forms were eluted from the column using 1 mg/mL
HA-peptide in equilibration buffer. The sample was concentrated
using an Amicon Centricon (10 kDa molecular weight cut-off)
microconcentrator and subjected to SDS-PAGE. Area of the
polyacrylamide gel containing different forms of SMP30 (identified
by western blotting of a duplicate lane on the same gel) was sliced
into 2 mm pieces, and digested overnight at room temperature
using the Ettan Spot Digester (GE Healthcare, Piscataway, NJ;
ITSI BioSciences, Johnstown, PA) as previously reported [43].
The plate containing the digests were evaporated to dryness,
reconstituted with ultra pure water and sequenced by tandem
mass spectrometry as described earlier [44]. Specifically, nano-
flow LC-MS/MS was carried out with nanobore electrospray
columns constructed from 360 mm o.d., 75 mm i.d. fused silica
capillary with the column tip tapered to a 15 mm opening. The
columns were packed with 200 A 5 mm C18 beads (Michrom
BioResources, Auburn, CA) to a length of 10 cm. The mobile
phase for gradient elution consisted of: a) 0.3% acetic acid, 99.7%
water, and b) 0.3% acetic acid, 99.7% acetonitrile. The flow
through the column was split pre-column to achieve a flow rate of
350 nl/min. All tandem mass spectra were acquired on a Thermo
DECA XP Plus or LTQ ion trap mass spectrometer (Thermo
Corporation, Waltham, MA) with the needle voltage set at 3 kV.
Ion signals above a predetermined threshold automatically
triggered the instrument to switch from MS to MS/MS mode
for generating fragmentation spectra. The obtained MS/MS
spectra were searched against the NCBI non-redundant protein
sequence database using the SEQUEST computer algorithm [45].
Treatment with inhibitors of proteolysis
HEK-293A cells were treated with various tool compounds at
concentrations as indicated along with infection by Ad-SMP30-
HA (20 VP/cell) and cultured for 24 h. Equal volume of DMSO
served as control. The cells were then harvested, lysed with SDS-
PAGE sample buffer containing 5% b-mercaptoethanol, analyzed
by SDS-PAGE and western blotted using anti-HA antibody.
Treatment with ubiquitin proteasome pathway enzymes
using S-100 Hela degradation system
HEK-293A cells at maximal expression of SMP30 were lysed
with 50 mM HEPES buffer (pH 7.6) and the supernatant was
treated with S-100 Hela degradation mixture according to the
manufacturer’s instructions (Boston Biomedicals, Cambridge,
MA). The S-100 Heal degradation mixture contains reagents to
allow controlled degradation of proteins through the ubiquitin
proteasome pathway. The reaction mixture was then subjected to
SDS-PAGE followed by western blotting using the anti-HA
antibody.
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